- Amanat Acquisition Corp announced a definitive business combination with obesity biopharma Corxel US.
- Transaction expected to yield approx. $300M in gross proceeds, funding operations through 2029.
- Corxel plans to advance oral GLP-1 RA CX11 into global Phase 3 after positive Phase 2 weight loss data (up to 11.5% at Week 36).
?? Positive AI Sentiment (+3.0 / 10)
Observed market reaction after signal
4h -0.49% · Peak +6.56%